Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer

Kefeli, UmutArslan, ÇağatayYıldırım, Mahmut EmreIşıkdoğan, AbdurrahmanKaradurmuş, NuriKarabulut, Bülent2022-12-272022-12-272021Kefeli, U., Arslan, Ç., Yıldırım, M.E., Işıkdoğan, A., Karadurmuş, N., Karabulut, B. (2021). Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer. Journal of Clinical Oncology, 39(15 Sup.(Meeting abstract e15561))0732-183X1527-7755https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.e15561https://hdl.handle.net/11468/11143Background: Efficacy of anti-angiogenic and anti-EGFR agents has been demonstrated metastatic colorectal cancer (mCRC). Real-world evidence is especially important to detect the findings of patients outside of clinical trials.eninfo:eu-repo/semantics/closedAccessReal-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancerReal-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancerConference Object3915 (Sup. (Meeting abstract e15561))WOS:00070812030122610.1200/JCO.2021.39.15_suppl.e15561Q1